SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer

Inclusion criteria

• . age:18-70 years
• . Histologically or cytologically confirmed locally advanced and/or metastatic NSCLC or recurrent NSCLC (≤9 months from date of diagnosis to randomized ), epidermal growth factor receptor-wild type, Anaplastic Lymphoma Kinase-wild type or unknown mutation
• . At least one lesion that can be accurately measured and has not been received local treatments such as radiotherapy and cryotherapy
• . Relapse or failure of one first line prior platinum-based chemotherapy
• . Eastern Cooperative Oncology Group performance status 0 or 1
• . Life expectancy of at least 12 weeks
• . Adequate organ and bone marrow function as defined below(no blood transfusion or drugs for leucopenia and Platelet within 14 days before screening): (1) HB≥90g/l (2) ANC≥1.5×10\^9/l (3) PLT≥100×10\^9/l (4) BIL\<1.25×upper limit of normal (5) Alanine Aminotransferase and/or AST\<2.5×upper limit of normal (\< 5×upper limit of normal for patients with liver metastasis) (6) Cr≤1.25×upper limit of normal or Creatinine clearance rate\>45ml/min ( Cockcroft-Gault Formula) (7) Cholesterol≤1.5×upper limit of normal, Triglyceride≤2.5×upper limit of normal (8) Left ventricular ejection fraction (LVEF) greater than lower limit of normal